Workflow
Adaptive immune system regulation
icon
Search documents
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
Prnewswire· 2025-06-25 10:59
Core Insights - Q32 Bio Inc. has appointed Dr. Adrien Sipos as Interim Chief Medical Officer, succeeding Dr. Jason Campagna, who is leaving the company [1][2] - Dr. Sipos brings over 25 years of experience in clinical development and medical affairs, particularly in Immunology and Inflammation [1][2] - The company is advancing its Phase 2a clinical trial for bempikibart, a treatment for alopecia areata, with topline results expected in the first half of next year [2][3] Company Overview - Q32 Bio is a clinical stage biotechnology company focused on developing therapies for alopecia areata and other autoimmune and inflammatory diseases [3] - Approximately 700,000 individuals in the U.S. are affected by alopecia areata, which significantly impacts their lives and has limited treatment options [3] - Bempikibart (ADX-914) is a fully human anti-IL-7Rα antibody that aims to re-regulate adaptive immune function and is currently in a Phase 2 program [3] Leadership Background - Dr. Sipos previously served as President and Chief Medical Officer at PRAXICO Inc., advising biopharmaceutical companies on clinical development [2] - She has held significant roles at Biogen, Sanofi Genzyme, and Eli Lilly, focusing on immunology and clinical development [2] - Dr. Sipos holds a Ph.D. in Clinical Immunology and an M.D. specializing in clinical immunology and endocrine care [2]
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
Prnewswire· 2025-03-11 10:59
Core Insights - Q32 Bio presented encouraging clinical data for bempikibart in treating alopecia areata (AA) at the 2025 American Academy of Dermatology Annual Meeting, indicating its potential as a differentiated treatment option [1][2][6] - The company is on track to initiate the SIGNAL-AA open-label extension and Part B of the Phase 2a clinical trial in the first half of 2025, with topline data expected in the first half of 2026 [1][6] - As of December 31, 2024, Q32 Bio reported cash and cash equivalents of $78.0 million, which is expected to fund operations into the second half of 2026 [1][4] Clinical Development - Bempikibart, a fully human anti-IL-7Rα antibody, demonstrated clinically meaningful activity in a difficult-to-treat patient population with severe AA, showing continued effects after treatment cessation [6][7] - In the Phase 2a Part A trial, patients exhibited a deepening response in Severity of Alopecia Tool (SALT) scores, with all 12 patients who responded maintaining or achieving further hair growth during the follow-up period [6] - The upcoming SIGNAL-AA Part B trial will involve approximately 20 evaluable patients, with dosing regimens including an initial loading dose of 200mg weekly for four weeks, followed by a maintenance dose every other week [6] Financial Performance - For the quarter ended December 31, 2024, Q32 Bio reported a net loss of $14.2 million, a significant reduction from a net loss of $27.1 million in the same quarter of 2023 [4][12] - Research and development expenses increased to $10.5 million from $8.3 million year-over-year, primarily due to higher clinical trial and manufacturing costs [4][12] - General and administrative expenses rose to $4.0 million from $2.8 million, attributed to increased stock-based compensation and public company-related costs [4][12]